Repligen (RGEN) Tops Q2 EPS by 3c

Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $29.2 million versus the consensus estimate of $24.75 million.

GUIDANCE:

Repligen sees FY2016 EPS of $0.42-$0.48, versus the consensus of $0.47. Repligen sees FY2016 revenue of $101-105 million, versus the consensus of $99.5 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance